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Background: Antiarrhythmic agents may aﬀect electrical remodeling but little is known
regarding clinical cases. We evaluated ﬁbrillation cycle length (FCL) of atrial ﬁbrillation (AF)
by spectral analysis of ﬁbrillation waves (FW) in surface ECG for patients on antiarrhythmic
agents.
Methods and Results: 18 patients (14 males; 58 2 year-old) with paroxysmal AF (pAF)
lasting over 30 minutes recorded by Holter ECG were enrolled. FW was puriﬁed by
subtraction of QRS-T, and calculated by fast Fourier transformation analysis. FCL was
deﬁned as reciprocal of mean peak frequency. Temporal variability was expressed as FCL
coeﬃcient of variation (FCL-CV). FCL and FCL-CV were calculated at 0, 1, 5, 10, and 30
minutes after the onset of AF. We evaluated three groups: control group (6 patients with no
medication), class I group (6 patients with pilsicainide or ﬂecainide), and bepridil group (6
patients with bepridil). FCL showed quick-shortening at ﬁrst minute in control group
(p < 0:001), and relatively slow-shortening in class I group. In bepridil group, FCL was not
signiﬁcantly shortened within 30 minutes. FCL-CV did not change, but was signiﬁcantly
larger in bepridil group.
Conclusions: FCL of pAF showed signiﬁcant shortening in control group, but FCL
shortening was suppressed and FCL-CV was larger in bepridil group. This result may indicate
the speciﬁc eﬀect of bepridil for electrical changes in early phase of pAF.
(J Arrhythmia 2009; 25: 135–141)
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Introduction
Atrial ﬁbrillation (AF) is one of the most common
supra-ventricular tachy-arrhythmias1) characterized
by rapid and irregular activation of the atrium.2)
Although the importance of automatic triggers
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originating from the pulmonary veins has been
emphasized in clinical AF,3) the electrophysiological
property of the atrium is still an important factor to
maintain multiple random reentrant rhythms as the
driver of AF.4) Electrical remodeling occurs by
inappropriate rapid atrial activation or atrial wall
stretch, and it puts the atrium in a more suitable
condition for AF maintenance, which is character-
ized by shortening of the wavelength as a result of
shortening atrial refractoriness and the decrease in
conduction velocity.5) To evaluate these changes in
atrial electrophysiological properties directly, an
electrophysiological study should be performed,
but this invasive study cannot be repeated easily.
However, analysis of ﬁbrillation waves can evaluate
atrial electrophysiological properties or the complex-
ity of multiple waveforms and this non-invasive
method can be repeated at any time, even in clinical
cases.6–8) As the progression of atrial electrical
remodeling will result in smaller and more complex
reentrant circuits on the surface of the atrium and
may cause more fractionated ﬁbrillation waves on
surface ECG, it can be evaluated in clinical cases
through precise analysis of ﬁbrillation waves by
spectral analysis.9)
Through the results of several experimental
reports,10,11) antiarrhythmic agents are expected to
aﬀect the progression of atrial electrical remodeling
even in clinical AF, but little is known about these
eﬀects mainly because of the diﬃculty in evaluating
electrophysiological properties. In the present study,
the eﬀect of antiarrhythmic agents on the progres-
sion of atrial electrical remodeling was evaluated
using spectral analysis of atrial ﬁbrillation waves on
surface ECG in patients with paroxysmal AF.
Methods
Subjects and Study protocol
Holter ECG was recorded in 145 consecutive
patients with paroxysmal AF, and episodes of
paroxysmal AF that were sustained over 30 minutes
could be recorded in 18 patients (14 men and 4
women, age: 58 2 years). Paroxysmal AF was
deﬁned as self-terminated AF within the recording of
Holter ECG and ﬁbrillation waves during recorded
paroxysmal AF were evaluated in this study. All
patients underwent basic physical examination, 12-
lead ECG, echocardiography, and laboratory testing,
and none had exhibited any structural heart disease
except for 1 patient with mild mitral stenosis.
Analyses of ﬁbrillation waves
Data from standard lead CM1 of Holter ECG were
used for spectral analyses. Data were digitally stored
by A/D exchange at a sampling rate of 1 kHz, and
QRS-T complexes were subtracted using a template
matching algorithm.12) Frequency analyses were
performed on a microcomputer (BIMUTUS II,
Kissei Comtec Co., Ltd, Matsumoto, Japan). Fre-
quency analysis of the subtracted ECG involved 3
steps: (1) bandpass ﬁltering, (2) application of a
Hamming window and (3) 4096-point fast Fourier
transformation. A 50% overlap of adjacent spectral
analyses allowed the use of an average of 20 periods
of analysis within a single 44 second data set.12)
After spectral analysis, recordings were displayed as
power spectra, which were quantiﬁed by measuring
the peak frequency signal with the maximum
magnitude derived from each period. The peak
frequency of the spectrum in the 3–12Hz range was
converted to a cycle length (CL in ms = 1,000/
frequency), deﬁned as the ﬁbrillation cycle length
(FCL) averaged from 20 periods (44 seconds).
Temporal variability was expressed as the FCL
coeﬃcient of variation (FCL-CV) of 20 consecutive
periods.
The patients were divided into three groups in
accordance with the usage of antiarrhythmic agents,
i.e., the control group (6 patients with no medica-
tion), the class I group (6 patients with pilsicainide
75–150mg/day or ﬂecainide 100–200mg/day), and
the bepridil group (6 patients with bepridil 100–
200mg/day). FCL and FCL-CV were evaluated in
each episode of paroxysmal AF at 0, 1, 5, 10, and
30 minutes after the onset of AF, and data were
compared among the three groups.
Statistical analysis
All data are expressed as the mean SE. A paired
t-test was used to compare sequential data in the
same patients. One-way ANOVA was used for
comparison among three groups with diﬀerent
antiarrhythmic agents. A p value of <0:05 was
considered statistically signiﬁcant.
Results
Patient characteristics
Table shows the basic patient characteristics in this
study. Among the 3 groups, there was no signiﬁcant
diﬀerence in age, gender, left ventricular ejection
fraction (LVEF), left atrial dimension (LAD), ex-
istence of hypertension, and structural heart disease.
In the class I and bepridil groups, the duration of AF
tended to be shorter, but there was no signiﬁcant
diﬀerence among the 3 groups. The frequencies of
the paroxysms of AF during the Holter ECG also did
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not exhibit a signiﬁcant diﬀerence among the 3
groups. Additionally, the time of AF onset did not
show any distinctive tendency in this study.
Changes of FCL and FCL-CV during paroxysmal
AF
Figure 1 shows a representative example of ﬁbril-
lation wave analysis during paroxysmal AF recorded
on Holter ECG in the control group. The left panel
shows the data at 0 minutes, i.e., immediately after
the onset of paroxysmal AF, and calculated FCL and
FCL-CV were 198msec and 17% in this case. The
right panel shows the data at 30 minutes after the
onset of paroxysmal AF of the same episode in the
same patient. FCL was shortened to 173msec but
FCL-CV did not show an obvious change.
Figure 2 summarizes FCL and FCL-CV data in
the control group. FCL showed shortening from
a relatively early phase and the change became
signiﬁcant from 1 minute after the onset of parox-
ysmal AF (0 vs. 1min = 194 6 vs. 160 2ms,
p < 0:001). In contrast, FCL-CV did not show any
change along the time course of paroxysmal AF.
Comparison of the changes of FCL and FCL-CV
among patients with different antiarrhythmic agents
Figure 3 shows FCL and FCL-CV data in the class
I group, i.e., data in patients with class Ic antiar-
rhythmic drug therapy. In this group, FCL at the
onset of paroxysmal AF was longer than that in the
control group, probably because of the sodium
channel blocking eﬀect. Along the time course of
paroxysmal AF, FCL showed shortening but the
change was relatively slow and the change became
signiﬁcant at 5 minute after the onset of paroxysmal
AF (0 vs. 5min = 265 23 vs. 203 12ms,
p < 0:05). FCL-CV did not show any signiﬁcant
change along the time course.
0 4 8 12 [Hz] 0 4 8 12 [Hz]
41 s 41 s
0 s 0 s
0 minute 30 minutes
FCL:198 ms, FCL-CV 17% FCL:173 ms, FCL-CV  20%
Table clinical charactristics of the patients
control group
(n ¼ 6)
class I group
(n ¼ 6)
bepridil group
(n ¼ 6) p value
Age (years) 60  3 56  5 56  4 N.S.
Gender (F/M) 2/4 1/5 1/5 N.S.
Left vetricular ejection fraction (%) 63.2  2.7 65.5  2.5 62.9  0.9 N.S.
Left atrial dimension (mm) 39.8  2.3 42.3  1.6 39.7  1.7 N.S.
Hypertension 2/6 2/6 1/6 N.S.
Existence of heart disease (no. (%)) 1 (25) 0 (0) 0 (0) N.S.
Duration of AF (sec) 255.3  104.2 158.7  49.7 237.3  207.5 N.S.
Frequency of paroxysms of AF (time) 1.3  0.2 1.3  0.2 1.2  0.2 N.S.
Medications none pilsicainide 75–150mg/day orﬂecainide 100–200mg/day bepridil 100–200mg/day
Figure 1 Example of spectral analysis of
ﬁbrillation waves
This ﬁgure shows a representative example of
the analysis of ﬁbrillation waves during par-
oxysmal AF recorded on Holter ECG in the
control group. The left panel shows data at the
onset of paroxysmal AF, and FCL and FCL-
CV were 198msec and 17% in this case. The
right panel shows data at 30 minutes after the
onset of paroxysmal AF of the same episode in
the same patient. FCL was shortened to
173msec but FCL-CV did not show obvious
change. See text for details.
FCL: ﬁbrillation cycle length, FCL-CV: FCL
coeﬃcient of variation.
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Figure 4 shows FCL and FCL-CV data in the
bepridil group. In contrast to the other two groups,
FCL did not show signiﬁcant shortening during 30
minutes of observation, although it tended to be
slightly shortened along the time course. FCL-CV
also did not show signiﬁcant changes.
Figure 5 summarizes FCL and FCL-CV data of all
three groups. FCL at the onset of paroxysmal AF
was longer in the class I group than the control
group. Although FCL at the onset of paroxysmal AF
in the bepridil group tended to be longer than the
control group, the diﬀerence was not signiﬁcant. At
FCL FCL-CV
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Figure 2 Data in the control group
This ﬁgure shows FCL and FCL-CV data in the
control group. FCL showed shortening from a
relatively early phase and the change became
signiﬁcant from 1 minute after the onset of
paroxysmal AF (0 vs. 1min = 194 6 vs.
160 2ms, p < 0:001). FCL-CV did not show
any change along the time course of paroxysmal
AF. See text for details.
FCL: ﬁbrillation cycle length, FCL-CV: FCL
coeﬃcient of variation.
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Figure 3 Data in the class I group
This ﬁgure shows FCL and FCL-CV data in the
class I group. FCL at the onset of paroxysmal
AF was longer than that in the control group.
Along the time course of paroxysmal AF, FCL
showed relatively slow shortening and the
change became signiﬁcant at 5 minutes after
the onset of paroxysmal AF (0 vs.
5min = 265 23 vs. 203 12ms, p < 0:05).
FCL-CV did not show any signiﬁcant change
along the time course. See text for details.
FCL: ﬁbrillation cycle length, FCL-CV: FCL
coeﬃcient of variation.
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Figure 4 Data in the bepridil group
This ﬁgure shows FCL and FCL-CV data in the
bepridil group. In contrast to the other two
groups, FCL did not show signiﬁcant shortening
during 30 minutes of observation although it
tended to be slightly shortened along the time
course. FCL-CV did not show signiﬁcant
changes either. See text for details.
FCL: ﬁbrillation cycle length, FCL-CV: FCL
coeﬃcient of variation.
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several later time points, FCLs in the class I and
bepridil groups were longer than those in the control
group although FCL in the class I group showed
signiﬁcant shortening along the time course. FCL-
CV did not show any signiﬁcant changes in any
group along the time course, but FCL-CV in the
bepridil group was larger than the control group at
several time points.
Discussion
Documentation of the shortening of FCL during
paroxysmal AF
It has been reported that atrial refractoriness
would be shortened by continuous rapid atrial
activation as atrial electrical remodeling.13) Although
it would take a longer period for the atrial tissue to
achieve structural remodeling including intercellular
ﬁbrosis or the down-regulation of several ion
channels, the shortening of atrial refractoriness
would be observed from the very early phase of
rapid activation.13) This relatively quick response of
atrial refractoriness could be evaluated by electro-
physiologic study,2,14) but practically, it is diﬃcult or
impossible to evaluate in clinical episodes of AF. In
the present study, atrial refractoriness was indirectly
evaluated by the FCL obtained from the spectral
analysis of ﬁbrillation waves on surface ECG.
The analysis of FCL from the surface ECG trace
has been evaluated in several reports. We have
previously reported that the f-f interval on surface
ECG showed a direct correlation with the atrial
eﬀective refractory period even though it was
detected manually.15) Spectral analysis of the ﬁbril-
lation wave is another objective method for the
evaluation of atrial electrophysiological properties
and several reports have documented that the
dominant power frequency in spectral analysis
would show direct correlation with the frequency
of local atrial activation, i.e., the local a-a interval
during AF.9,16–20) FCL could be deﬁned as the
reciprocal of the peak power frequency in spectral
analysis,9,18–20) and the response of the change in
FCL has been reported to be a predictor of the eﬀect
of antiarrhythmic agents on the interruption of
AF.9,12,16) Even in the process of the progression of
atrial electrical remodeling, the analysis of ﬁbrilla-
tion waves on surface ECG has been reported to be
useful.9,15) Fujiki et al.9) have reported that the AF
duration showed a signiﬁcant inverse correlation
with the mean FCL (r ¼ 0:79, p < 0:01), and FCL
shortening is considered to be related with the
progression of atrial electrical remodeling.
Effects of antiarrhythmic agents on the changes
in FCL during paroxysmal AF
In accordance with the results of several clinical
studies,9,12,16) it would be expected that antiarrhyth-
mic agents would aﬀect changes in FCL during
electrical remodeling in paroxysmal AF. In our
present study, we focused on the early phase FCL
shortening, which was classically called ‘‘early phase
electrical remodeling’’, but it would simply reﬂect
the physiological response to the rapid atrial ﬁring.
The result was that class Ic antiarrhythmic agents
prolonged FCL at the onset of paroxysmal AF and
suppressed FCL shortening in the very early phase,
i.e., around 1 minute after the onset of AF, in
comparison with the control group. The prolongation
of FCL could be understood by prolongation of the
length of the active reentrant circuit as the result of
the sodium channel blocking eﬀect.13) The suppres-
sive eﬀect of class Ic agents on FCL shortening
could be understood as a suppressive eﬀect on the
control class I bepridil
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Figure 5 Comparison of data among the
three groups
This ﬁgure summarizes all FCL and FCL-CV
data of three groups. FCL at the onset of
paroxysmal AF was longer in the class I group
than the control group. At several later time
points, FCLs in the class I and bepridil groups
were longer than those in the control group
although FCL in the class I group showed
signiﬁcant shortening along the time course.
FCL-CV in the bepridil group was larger than
the control group at several time points. See text
for details.
FCL: ﬁbrillation cycle length, FCL-CV: FCL
coeﬃcient of variation.
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early electrophysiological changes, as reported pre-
viously,9) and at the end of the protocol, i.e., after 30
minutes, the value of FCL remained signiﬁcantly
larger than that in the control group. But by temporal
evaluation, the value of the FCL at 5 minutes was
signiﬁcantly shorter than that at the start of the
protocol, and its shortening continued to the end of
the protocol in the class I group. In other words,
the class Ic agents prolonged the absolute value of
FCL, but did not suppress the temporal changes of
FCL. In contrast, bepridil, a new antiarrhythmic
agent, showed a diﬀerent eﬀect from that of class
Ic antiarrhythmic agents. Although bepridil also
exhibited slight prolongation of FCL at the onset of
AF, the diﬀerence was not signiﬁcant in comparison
with the control group. This result could be under-
stood as a result of the relatively weaker sodium
channel blocking eﬀect of bepridil than class I
antiarrhythmic agents.21,22) In contrast, FCL short-
ening in the later phase was not observed in the
bepridil group, at least in 30 minute of observation
of the paroxysmal AF in this study. This seems to
indicate a relatively long-lasting anti-FCL shorten-
ing eﬀect of this agent23) in comparison with class Ic
agents. At the evaluation point of 30 minutes, the
absolute values of FCLs in class I and bepridil group
were identical. But the temporal FCL changes along
the time course were diﬀerent. These would be an
additional explanation of the speciﬁc eﬀect of
bepridil for drug-refractory or long-lasting persistent
AF in clinical cases.18,24)
On the other hand, FCL-CV became larger in the
bepridil group in comparison with the control group.
Although the meaning of FCL-CV on surface ECG is
unclear, larger FCL-CV, i.e., the variety of power
frequency in spectral analysis, can be understood as
the existence of plural heterogenic reentrant circuits
in the atria.9) Therefore, this data may be compatible
with results indicating the increase in dispersion of
refractoriness in the ventricle.25) As the decrease in
FCL-CV is also observed in patients with long-
lasting persistent AF,9,10) this increase in FCL-CV
might be also considered as part of the anti-electrical
remodeling eﬀect of bepridil during AF.
The mechanisms of the eﬀects of these antiar-
rhythmic agents are not clear. Class Ic antiarrhythmic
agents might exhibit a decrease in intracellular Ca2þ
overload as a result of enhanced movement of the
Naþ-Ca2þ exchanger,26) and it would suppress elec-
trical remodeling because Ca2þ overload is consid-
ered to play a key role in its promotion, especially
in the early phase.14,27) Bepridil may also decrease
intracellular Ca2þ overload by its direct action on the
L-type Ca2þ channel as well as its weak action on the
sodium channel. The L-type Ca2þ channel blocking
eﬀect may also exhibit a rate control eﬀect as a result
of the suppressive eﬀect on atrio-ventricular nodal
conduction. The up-regulation of ion channels28)
might not be a direct mechanism because observation
of the duration of paroxysmal AF in this study is too
short, but changes in the basic expressions of ion
channels might be involved in the mechanism.
Clinical implication
It is unclear whether these eﬀects of antiarrhyth-
mic agents on the electrophysiological ﬁndings in
the early phase of pAF will aﬀect the progression of
the electrical remodeling. Because the progression of
the electrical remodeling depends on the frequency
and duration of rapid atrial ﬁring, longer FCL during
pAF kept by the eﬀects of antiarrhythmic agents
is considered to protect the atrium from the early
progression of the electrical remodeling. Interest-
ingly, the mean FCL at 30 minute observation were
similar in class Ic and bepridil groups although the
initial responses were diﬀerent, and they were both
signiﬁcantly longer than the control. This result may
lead to preventive eﬀects of antiarrhythmic agents on
the progression of the electrical remodeling in pAF
patients, although the actions were diﬀerent from
each other.
In the previous reports, the longer FCL and larger
FCL-CV are predictive markers for the eﬃcacy of
antiarrhythmic agent for AF interruption.9) In the
present study, the levels of the mean FCLs were
similar between class Ic and bepridil groups, but
FCL-CV was always larger in the bepridil group than
the others. Because this parameter indicates the time-
course instability of AF reentrant circuits, and is
usually larger in patients with a shorter history of
AF,19,20) bepridil might be considered to maintain the
instability of AF circuits and easy AF interruption by
antiarrhythmic agents.
Conclusions
FCL evaluated in the spectral analysis of ﬁbrilla-
tion waves on surface ECG showed signiﬁcant
shortening along the time course after the onset of
AF in clinical cases. FCL shortening was partly
suppressed by class Ic antiarrhythmic agents, and
almost totally suppressed by bepridil during our 30
minute observation. FCL-CV was also greater in
the bepridil group. These results may indicate the
suppressive eﬀect of electrical changes of antiar-
rhythmic agents during the very early phase of
paroxysmal AF.
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